Imidazoles II. Synthesis and Some Pharmacolog-ical Properties of Nitroimidazol-1-yl-ethylsulphonamides by Z. Crnić & B. Glunčić
CROATICA CHEMICA AC TA CCACAA 54 (2) 225-232 (1981) 
CCA-1278 
YU ISSN 0011-1643 
UCD 547.78 
Original Scientific Paper 
Imidazoles II. Synthesis and Some Pharmacolog-ical Properties of 
Ni troimidazol-1-yl-ethy lsul phonamides1 
z. Crnic and B. Gluncic 
PLIV A, Pharmaceutical, Chemical, Food and Cosmetic Industry, Research Institute, 
I. L. Ribara 89, 47000 Zagreb , Yugoslavia 
Received May 12, 1980 
Starting from 1-aminoethyl-5-nitroimidazoles 9-12, and their 
4-nitro isomers 13-16, sulphonamido derivatives 17-40 and 45-68 
were prepared by condensation with various arylsulfonylchlorides. · 
Para-amino derivatives 41-44 and 69-72 were obtained by acidic 
hydrolysis of the intermediary para-acet.amido derivatives 22, 28, 
34, 40, 50, 56, 62, and 68. Compounds 2 and 24-26 exhibited anti-
trichomonal activity comparable to that of metronidazole, while 
the bacteriostatic activity of compounds 2, 6, 10, 23-28, 42, 55, 56, 
and 70 was comparable to that of sulfaphenazole. 
INTRODUCTION 
The well-established antitrichomonal activity of 1-substituted-5-nitroimi-
dazoles2•'1 on one hand, and the broad spectrum of bacteriostatic activities of 
sulphonamides4 on the other, prompted us to prepare a series of 4- and 
5-nitroimidazol-l'-yl-ethylsulphonamides 17-72 and to test them for both 
types of biological activity. This paper briefly reports the synthesis, spectral 
characteristics, and some pharmacological properties of these compounds. 
RESULTS AND DISCUSSION 
Chemistry. Starting N1-~-aminoethyl nitroimidazoles 9-16 were prepared 
by hydrolysis of the corresponding N-acetylamino derivatives 1-8, recently 
described by us0•6 (Scheme 1). 
They, in turn, were condensed with a number of para-substituted ben-
zenesulfonylchlorides affording sulphonamides 17-40 and 45-68. Para-amino 
derivatives 41-44 and 69-72 were obtained on subsequent hydrolysis of the 
intermediate acetamido derivatives 22, 28, 34, 40, 50, 56, 62, and 68. 
Infrared spectra of all prepared compounds exhibited characteristic fre-
quencies at 1520-1560 cm-1 (µ asN-0, s) and at 1330-1370 cm-1 (µ5N-O, vs)'. 
Sulphonamide groups regularly exhibited characteristic bands at 1300-1320 
cm-1 (µ asS-0, vs) and at 1145-1155 cm-1 (µ 5S-O, vs)R. The UV spectra of the 
4-nitro isomers showed the maxima in the region 283-310 nm, while the 
5-nitro isomers have shown the same at 295-316 nm. It is characteristic that 
of two isomeric compounds, the absorption maximum of 5-nitro isomer is 
shifted approximately 6-10 nm towards the longer wave length9• 






















2, 6, 10, 14, 23-28, 42, 51-56, 70 R1 = CHa, R2 = H 
3, 7, 11, 15, 29-34, 43, 57-62, 71 R1 = H, R2 = CHa 
4, 8, 12, 16, 35-40, 44, 63-68, 72 R1 = R2 = CHs 
Ra = H, CHa, Cl, Br, N02, NHCOCH3 
In addition, each of the compounds 17-72 exhibited an additional cha-
racteristic maximum in the region of 221-276 nm. 
Other characteristic spectral and analytical data are given in the Tables 
I, II, and III. 
Pharmacology. In Table IV the results of in vitro investigations of tri-
chomonal10 and bacteriostatic activity11 of 1-substituted-2-methyl-5-nitro- and 
4-nitroimidazoles are presented. Preliminary investigations revealed that deri-
vatives of 5-nitroimidazoles 2 and 24-26 posses comparable antitrichomonal 
activity to that of the metronidazole [l-(2'-hydroxyethyl)-2-methyl-5-nitro-
imidazole], a well-known antitrichomonal agent2 • 
Bacteriostatic activities were determined on the species Streptococcus 
haemolyticus, Escherichia coli, Staphylococcus pyogenes aureus, Pseudomonas 
pyocinea, Klebsiella, Shigella Sonnei, and Bae. proteus mirabillis. The activities 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































IMIDAZOLES II 231 
comparable, except that they exhibited lower activity against Streptococcus 
haemolyticus, to that of sulfaphenazole taken as the standard with a well-know 
bacteriostatic properties12. 
EXPERIMENTAL 
Melting points are determined on Fisher-Johns melting point apparatus, and 
are uncorrected. The IR-spectra were recorded with a Model 257 G Perkin-Elmer 
spectrometer. The UV-spectra were recorded with an SP 800 Unicam spectrometer 
in ethanol 96°/o. The 'H-NMR spectra were run on the A-60 Varian instrument in 
DMSO-ds, with TMS as an internal standard. TLC was performed on silica gel 
plates (Merck, Kieselgel HF254) using chloroform-methanol (9 : 1) as the eluent. 
General Procedure for the Preparation of 5-Nitro-4-R2-, and 4-Nitro-5-R2 -1-
-(2'-aminoethyl)-2-R,-imidazoles (9-12 and 13-16) 
A solution of 5-nitro-4-R2- or 4-nitro-5-R2-l-(2-acetylaminoethyl)-2-R1-imidazole 
[1.98 g of 1, 5, 2.12 g of 2, 3, 6, 7, 2.26 g of 4.8; 10.0 mmol each] in hydrochloric acid 
250/o (20 ml) was heated under reflux for 4 h. The solvent was evaporated to dryness, 
a mixture of ethanol-ether (1 : 1) was added, and the product was filtered and 
recrystallized from ethanol 960/o to give compounds 9-16 listed in Table I. 
General Procedure for the Preparation of 5-Nitro-4-R2-, and 4-Nitro-5-R2-1-
-(2'-p-R3-benze1J,esulfonylaminoethyl)-2-R1-imidazoles (17-40 and 45-68) 
To an ice-water cooled solution of hydrochloride of 5-nitro-4-R2- or 4-nitro-
-5-R2-1-(2'-aminoethyl)- 2-R1-imidazole (l.92 g of 9, 13; 2.06 g of 10, 11, 14, 15; 2.75 g 
of 12; 2.20 g of 16; 5.0 mmol each), and sodium bicarbonate (2.95 g, 35.0 mmol) in 
water (30 ml) was added the solution of arylsulfonylchloride (0.97 g of benzenesulfo-
nylchloride, 1.05 g of tolylsulfonylchloride, 1.18 g of p-chlorobenzenesulfonylchloride, 
1.41 g of p-bromobenzenesulfonylchloride, 1.22 g of p-nitrobenzenesulfonylchloride, 
1.28 g of p-acetylaminobenzenesulfonylchloride; 5.5 mmol each) in methylethyl ketone 
(15 ml) over a period of 30 min, and the mixture was stirred at room temperature 
for next 3· hrs. Separated crystals were filtered, dissolved in diluted sodium hydroxide, 
and acidified to pH 6. Crude product was collected on a filter, washed with water, 
and recrystallized from ethanol 960/o to give pure compounds 17-40, and 45-68 
listed in Tables II and III. 
General Procedure for the Preparation of 5-Nitro-4-R2-, and 4-Nitro-5-R2-1-
-(2'-p-aminobenzenesulfonylaminoethyl)-2-R1-imidazoles (41-44 and 69-72) 
A mixture of 5-nitro-4-R2- or 4-nitro-5-R2-1-(2'-p-acetylaminobenzenesulfonyl-
aminoethyl)-2-R1-imidazole (1.77 g of 22, 50; 1.85 g of 28, 34, 56, 62; 1.91 g of 40, 68; 
5.0 mmol each), hydrochloric acid 150/o (12 ml), and ethanol (10 ml) was refluxed 
under stirring for 30 min. Thereafter solvent was evaporated in vacuo, the residue 
dissolved in water, and filtered. The filtrate was adjusted to pH 6,5-7, the preci-
pitate was collected on a filter, and recrystallized from ethanol 900/o to give pure 
compounds 41-44, and 69-72 listed in Tables II and III. 
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SAZETAK 
Imidazoli II. Priprava neka farmakolo'ska svojstva nitroimidazol-1'-il-
-etilsulfonamida 
z. Crnic i B. Glun cic 
Polazeci od 1-aminoetil-5-nitroimidazola 9-12 i njihovih 4-nitroizomera 13-16, 
koje smo pripravili hidrolizom odgovarajucih acetamido derivata 1-8, pripravljeni 
su sulfonamidi 17-40 i 45-68 kondenzacijom s rnznim arilsulfokloridima. Para-amino 
derivati 41-44 i 69-72 su dobiveni hidrolizom u kiselom intermedijernih para-aceta-
mido derivata 22, 28, 34, 40, 50, 56, 62 i 68 . Spojevi 2 i 24-26 pokazali su antitrihomo-
nalno djelovanje usporedivo s onim od metronidazola, dok se in vitro bakterio-
statska aktivnost spojeva 2, 6, 10, 23-28, 42, 55, 56 i 70 pokazala uporedivom s onom 
od sulfafenazola, izuzev n ize aktivnost: na Streptococcus haemolyticus. 
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